MedPath

Extended-Release Melatonin in Patients With Rapid Eye Movement Sleep Behavior Disorder

Not Applicable
Terminated
Conditions
Parkinson Disease
Rapid Eye Movement Sleep Behavior Disorder
Registration Number
NCT05307770
Lead Sponsor
Mayo Clinic
Brief Summary

The purpose of this research is to compare the efficacy of immediate versus extended-release melatonin as a supplement affecting the sleep cycle in patients with Parkinson disease and Rapid Eye Movement Sleep Behavior Disorder.

Detailed Description

Enrolled patients with Parkinson disease and previously diagnosed rapid eye movement sleep behavior disorder, who are being treated at Mayo Clinic in Florida, will be randomized to receive either immediate-release melatonin or extended-release melatonin and then will be crossed over to receive the opposite intervention. The study will consist of two treatment periods of 4 weeks separated by a washout period of 2 weeks.

Recruitment & Eligibility

Status
TERMINATED
Sex
All
Target Recruitment
25
Inclusion Criteria
  • Diagnosed with Parkinson's disease and rapid eye movement sleep behavior disorder.
  • Patient registered to Parkinson's disease database of Mayo Clinic Florida.
Exclusion Criteria
  • Patients who are using other sleep aids or medications (Clonazepam).
  • Patients who are not willing to undertake 1 week of washout period.
  • Patients who do not sign a consent for research.

Study & Design

Study Type
INTERVENTIONAL
Study Design
CROSSOVER
Primary Outcome Measures
NameTimeMethod
Change in sleep cycleBaseline and 4 weeks

Assessed by the self-reported modified Mayo Sleep questionnaire (MSQ) which consists of 8 questions related to sleep behavior in the past month.

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Mayo Clinic Florida

🇺🇸

Jacksonville, Florida, United States

Mayo Clinic Florida
🇺🇸Jacksonville, Florida, United States

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.